Postoperative ctDNA divides risk after head and neck squamous cancer surgery
A tumor-informed ctDNA assay identified a sharper postoperative risk signal than standard clinicopathologic selection in resected mucosal and cutaneous squamous cell carcinomas of the head and neck. In this institutional cohort of 110 consecutive patients with non-metastatic cSCC or HPV-negative HNSCC, investigators tested circulating tumor DNA after curative-intent surgery and before adjuvant therapy to see whether molecular residual disease could separate patients who needed escalation from those who did not. After a median follow-up of 34 months, a single detectable postoperative MRD result carried a sensitivity of 71.0% and specificity of 85.1% for downstream disease recurrence. The signal was not subtle: detectable MRD tracked with inferior overall survival, locoregional recurrence, and distant metastasis.
Residual tumor DNA in blood is biologically plausible in this setting because surgery can clear gross disease while leaving behind microscopic nests in the surgical bed, lymphatic channels, or distant micrometastatic sites. In head and neck squamous cancers, where locoregional relapse can drive substantial morbidity, a molecular readout after resection may capture viable tumor burden that pathology alone cannot quantify. Clinicopathologic features still matter, but they are imperfect surrogates for whether tumor remains active. This cohort suggests ctDNA can serve as a direct readout of that residual disease burden rather than a retrospective proxy.
Clearance after adjuvant treatment marked an intermediate group
Among patients with detectable postoperative MRD, 37.5% cleared ctDNA after adjuvant therapy and moved into an intermediate prognostic category. The finding matters because it separates persistence from response: a positive test before adjuvant treatment does not appear to be a fixed sentence, but neither does it resolve into a uniformly poor outcome once treatment begins. Some patients converted to ctDNA negativity, implying that postoperative therapy can still eradicate molecular disease in a meaningful subset.
The assay also outperformed traditional prognosticators and was predictive for adjuvant chemotherapy benefit. In practical terms, postoperative ctDNA did more than stratify baseline recurrence risk; it helped identify who was likely to gain from systemic intensification. That is a different clinical function from ordinary risk estimation. It moves the biomarker from passive prognostication toward treatment selection, which is the point at which molecular testing begins to alter postoperative decision-making rather than simply describe it.
The authors directly tested the premise that MRD positivity before adjuvant therapy would be prognostic and predictive. The data supported both roles. In a field where many patients are overtreated or undertreated because available criteria are blunt, a blood-based biomarker that can track residual disease, response to adjuvant therapy, and recurrence risk at once has immediate trial-design value.
Genomic alterations linked to higher MRD burden and poorer clearance
Certain tumor genomic alterations were associated with especially adverse molecular behavior. Patients with CCND1/CTTN amplification or CDKN2A/CDKN2B/MTAP deletions had MRD positivity rates of 60%. They were also less likely to clear ctDNA during adjuvant therapy, with clearance rates of 17% versus 54% in comparison groups, and they experienced inferior 24-month disease-free survival of 30.0% versus 61.7%.
Those patterns are consistent with more aggressive tumor biology. Alterations affecting cell-cycle regulation and neighboring tumor suppressor pathways can plausibly support continued proliferation, immune evasion, and persistence after surgery. If microscopic disease is already genomically primed for growth, it may be less likely to disappear with local therapy alone and less likely to convert to a molecularly silent state after adjuvant treatment. The genomic data therefore reinforce the blood-based findings rather than merely decorating them.
The study also makes clear that not all MRD-positive patients behave the same. Some clear ctDNA after adjuvant therapy and enter a middle-risk group, while others carry alterations associated with low clearance and worse disease-free survival. For surgeons, radiation oncologists, and medical oncologists managing resected head and neck squamous cancers, that difference could eventually matter at the bedside: a postoperative blood test may help distinguish the patient who can be observed from the patient who needs intensification, and the patient whose molecular disease persists despite treatment.
What this means for postoperative trial design
The current study remains an institutional cohort, not a randomized treatment trial, and it was built around 110 consecutive patients with non-metastatic cutaneous or HPV-negative mucosal disease. Even so, the internal consistency of the findings is hard to ignore. A single postoperative MRD result carried meaningful sensitivity and specificity, aligned with survival outcomes, and identified a subgroup that appeared to benefit from adjuvant chemotherapy. The result is especially relevant because adjuvant decisions in these cancers still lean heavily on clinicopathologic risk features that can miss occult residual disease.
This is exactly the sort of setting where biomarker-adapted trials become necessary. If postoperative ctDNA can define high-risk patients more precisely than pathology alone, then future studies can assign adjuvant therapy by molecular risk rather than by broad anatomical or histologic criteria. That approach could reduce unnecessary treatment in molecularly negative patients while enriching intensification strategies for those with persistent MRD. It could also identify genomic subsets, such as those with CCND1/CTTN amplification or CDKN2A/CDKN2B/MTAP loss, that may need alternative escalation strategies because standard adjuvant therapy appears less effective at clearing ctDNA.
The unanswered question now is not whether postoperative ctDNA is biologically informative; it is how best to operationalize it in prospective care pathways. The next step is a trial structure that tests whether acting on MRD status improves recurrence outcomes without simply adding treatment to every patient who can tolerate it.